Hepatology International

Article	Citations
The safety profile of endoscopic variceal ligation in patients with esophageal varices	163
HBV in pregnancy: time to consider tenofovir alafenamide (TAF)	104
Platelets in acute liver failure: an innocent bystander or instigator?	80
Defining the evaluation standards for the cholangiocytic component in cHCC-CCA: a pathology-based perspective	79
Tenofovir alafenamide-related hyperlipidemia and cardiovascular risk	65
Midodrine plus propranolol versus propranolol alone in preventing first bleed in patients with cirrhosis and severe ascites: a randomized controlled trial	59
Clathrin light chain A facilitates small extracellular vesicle uptake to promote hepatocellular carcinoma progression	56
Beyond left versus right: from puncture site selection to clinical strategy in TIPS	55
Precision medicine for G-CSF in ACLF: the biomarker gap	54
Metabolically healthy obese and MAFLD: does weight status alone matter?	50
N-terminal propeptide of type 3 collagen-based sequential algorithm can identify high-risk steatohepatitis and fibrosis in MAFLD	48
Letter to the Editor: Comparison of diagnostic criteria for fatty liver disease in assessing cardiac dysfunction: a cross-sectional study	46
Commentary on “Comparison of relaxed verses standard cut-offs of rotational thromboelastometry for guiding blood product use before invasive procedures in advanced cirrhosis: a randomized controlled t	46
Comment on “Diabetes mellitus is linked to higher mortality in alcohol‑related acute‑on‑chronic liver failure”	45
Response to: “Is laparoscopic hepatectomy superior to laparotomic hepatectomy? The debate continues”	44
Exosome GLUT1 derived from hepatocyte identifies the risk of non-alcoholic steatohepatitis and fibrosis	44
Breaking bottlenecks: the future of hepatocellular carcinoma clinical trials and therapeutic targets	44
Comment on “Comparison of diagnostic criteria for fatty liver disease in assessing cardiac dysfunction: a cross-sectional study”	43
Antibiotic prophylaxis in upper gastrointestinal bleeding with Child-Pugh A cirrhosis: need for objective infection markers and broader studies	43
Pure laparoscopic versus open left lateral hepatectomy in pediatric living donor liver transplantation: a review and meta-analysis	42
Machine learning models in the prediction of 1-year mortality in patients with advanced hepatocellular cancer on immunotherapy: a proof-of-concept study	41
Predictive value of soluble PD-1 for HBsAg loss in HbeAg-negative patients with chronic hepatitis B: results from a prospective study	41
Noninvasive risk stratification of liver nodule development in Fontan-associated liver disease using liver stiffness measurement	40
Antioxidant, selenium and risk of nonalcoholic fatty liver disease, more than causality	40
Good outcomes of living donor liver transplant in primary sclerosing cholangitis: an experience from North India	40

Can living donor liver transplantation provide similar outcomes to deceased-donor liver transplantation for hepatocellular carcinoma? A systematic review and meta-analysis	40
Development of nomograms to predict outcomes for large hepatocellular carcinoma after liver resection	40
Distinct on-treatment HCC risks associated with different decompensation events in HBV patients with cirrhosis	39
The promise of incretin-based pharmacotherapies for metabolic dysfunction-associated fatty liver disease	38
Comment on “Machine learning prediction of rapid HBsAg seroclearance at week 24 in inactive carriers treated with pegylated interferon”	38
The impact of an increased Fibrosis-4 index and the severity of hepatic steatosis on mortality in individuals living with diabetes	37
p53 regulates glucose metabolic reprogramming in MASLD-related hepatocellular carcinoma via modulating mitochondrial pyruvate carriers	36
Methodological reflections on vasoconstrictor use in refractory ascites: bridging trial rigor and real-world relevance	35
Small extracellular vesicles derived from lipotoxic hepatocytes transport FASN to promote hepatic stellate cell activation	35
Efficacy and safety of durvalumab rechallenge in advanced hepatocellular carcinoma patients refractory to prior anti-PD-1 therapy	34
Impact of CT-relevant skeletal muscle parameters on post-liver transplantation survival in patients with hepatocellular carcinoma	34
Targeting immuno-metabolism and anti-viral immune responses in chronic hepatitis B	33
Prevalence and impact on the outcome of myosteatosis in patients with cirrhosis: a systematic review and meta-analysis	33
Reply to: “developing real‑world prognostic models for patients with advanced hepatocellular carcinoma: CRAFITY, mALF and beyond”	33
Letter to the editor: Treating portal vein thrombosis in cirrhosis: is anticoagulation therapy overestimated?	33
Correction to: Targeting ferroptosis in hepatocellular carcinoma	32
The dynamic patterns of metabolic-associated fatty liver disease and its severity and risk of cardiovascular disease	31
An algorithm for simplified hepatitis C virus treatment with non-specialist care based on nation-wide data from Taiwan	31
Comments on “Three‑year overall survival in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab”	30
Liver cancer and hepatic decompensation events in patients hospitalized with viral hepatitis in Spain	30
Drug–drug interactions between direct-acting antivirals and co-medications: a territory-wide cohort study	30
Refining the definition of acute autoimmune hepatitis: implications for classification and prognosis	30
Metabolic dysfunction associated fatty liver disease in healthy weight individuals	29
Prospects for treatment of esophageal varices considering the safety of endoscopic band ligation	29
Metabolic dysfunction-associated steatotic liver disease increases the incidence of metachronous liver metastases from TNM stage 0–II colorectal cancer	28
Novel and simplified model for the precise identification of concurrent bacterial infections in patients aged 60 years and older with acute-on-chronic liver diseases: a nationwide, multicentre, prospe	27
Identifying the early predictors of non-response to steroids in patients with flare of autoimmune hepatitis causing acute-on-chronic liver failure	27
Lusutrombopag for thrombocytopenia in Chinese patients with chronic liver disease undergoing invasive procedures	27
Role of splenic hepatic elastography ratio in differentiating non-cirrhotic portal fibrosis and chronic liver disease in children and adolescents	27
Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients	26
Methodological considerations in linking depression to metabolic dysfunction-associated steatotic liver disease: insights for future study design	26
Enhancing the understanding and management of metabolic dysfunction-associated steatotic liver disease in colorectal cancer patients: insights and future directions	26
Regarding the methodological aspects of the TabPFN model for predicting post-TIPS hepatic encephalopathy	26
Gut microbes associated with functional cure of chronic hepatitis B	26
A combined model of HBcrAg, anti-HBc, and anti-HBs predicts recurrence after functional cure of chronic hepatitis B	26
APASL STC 2025, Istanbul	26
The relationship between CXCR6+CD8+T cells and clinicopathological parameters in patients with primary biliary cholangitis	26
Liver-derived extracellular vesicles from patients with hepatitis B virus-related acute-on-chronic liver failure impair hepatic regeneration by inhibiting on FGFR2 signaling via miR-218-5p	26
Maternal and perinatal outcome in pregnancies complicated with portal hypertension: a systematic review and meta-analysis	26
Native liver survival with therapeutic plasma exchange in acutely decompensated hepatic Wilson Disease: revisiting the Dhawan index	25
Reply to letter to editor “Hepatic irAEs, ICI Continuation, and Survival: Methodological Perspectives and Future Directions”	25
Correction: The interplay between lymphatic system and portal hypertension: a comprehensive review	25
Immune biomarkers predicting response to G-CSF in acute-on-chronic liver failure: results from a GRAFT trial sub-study	25
The impact of artificial liver support system on intestinal microbiota and serum bile acid profiles in patients with acute-on-chronic liver failure: a prospective cohort study	25
Anti-PD-L1 antibodies promote cellular proliferation by activating the PD-L1–AXL signal relay in liver cancer cells	25
Correction: Liver transplantation for acute-on-chronic liver failure	25
The immune microenvironment features and response to immunotherapy in EBV-associated lymphoepithelioma-like cholangiocarcinoma	24
Comment on “BRIX1 activated by mTORC1-SP1 signaling regulates ribosome biogenesis and alternative splicing to promote hepatocellular carcinoma progression”	24
Downregulated VISTA enhances Th17 differentiation and aggravates inflammation in patients with acute-on-chronic liver failure	24
Real-world treatment outcome with protease inhibitor direct-acting antiviral in advanced hepatitis C cirrhosis: a REAL-C study	23

Stage-specific impact of portal hypertension on outcomes after liver resection in hepatocellular carcinoma	23
Global prevalence, metabolic characteristics, and outcomes of lean-MAFLD: a systematic review and meta-analysis	23
MAFLD, patient-centred care, and APASL	23
Liver decompensation: the yard stick that measures indications and adverse effects of human albumin infusion	22
Fecal microbiota transplantation in alcoholic hepatitis: new treatment paradigm or a shot in the dark?	22
Comment on: Low-risk individuals with primary biliary cholangitis and significant liver stiffness: prognosis and treatment	22
Benefit of adjuvant radiotherapy for gallbladder cancer: a comparability-based meta-analysis	21
Enhancing the prognostic value of inflammatory markers in hepatocellular carcinoma: a thoughtful discussion	21
Correction to: Exosomal miR-200b-3p induce macrophage polarization by regulating transcriptional repressor ZEB1 in hepatocellular carcinoma	21
The effect of transition timing of regorafenib on treatment outcomes in unresectable hepatocellular carcinoma: a real-world study	21
The association between visceral adipocyte hypertrophy and NAFLD in subjects with different degrees of adiposity	20
Diagnostic yield and novel candidate genes by next generation sequencing in 166 children with intrahepatic cholestasis	20
Distinctly altered lipid components in hepatocellular carcinoma relate to impaired T cell-dependent antitumor immunity	20
A somatic mutation-derived LncRNA signatures of genomic instability predicts the prognosis and tumor microenvironment immune characters in hepatocellular carcinoma	20
Skeletal muscle alterations indicate poor prognosis in cirrhotic patients: a multicenter cohort study in China	20
Recombinant human serum albumin: a true therapeutic substitute or merely a serum level elevator?	20
Comment on ‘Immunomodulation by bepirovirsen may induce killing of infected hepatocytes (B-Together study)’	20
Low skeletal muscle mass is associated with more severe histological features of non-alcoholic fatty liver disease in male	20
Sleep patterns, genetic susceptibility, and risk of cirrhosis among individuals with nonalcoholic fatty liver disease	20
Distinct course of portal hypertension in patients with cirrhosis with gastric variceal bleeding as their first decompensation: a propensity score-matched study	19
AARC score and urine NGAL predict terlipressin non-response and mortality in patients with acute-on-chronic liver failure	19
Liver fat and a perturbed metabolic milieu: a consilience of factors driving liver cancer development	19
From comorbidity to catalyst: mechanistic and therapeutic implications of diabetes mellitus in alcohol-related acute-on-chronic liver failure	19
AGEX: a comprehensive database of clinically relevant genetic variants associated with Alagille syndrome across diverse populations	19
Liver and cardiovascular outcomes in lean non-alcoholic fatty liver disease: an updated systematic review and meta-analysis of about 1 million individuals	19
Australian best practice recommendations for transjugular intrahepatic portosystemic shunt (TIPS) in portal hypertension: a consensus statement	19
Temporal trends and regional variations in hepatocellular carcinoma etiology: a multinational study across Asia	19
ChIP-seq analysis found IL21R, a target gene of GTF2I–the susceptibility gene for primary biliary cholangitis in Chinese Han	19
Dual-etiology MAFLD: the interactions between viral hepatitis B, viral hepatitis C, alcohol, and MAFLD	19
Gender differences in non-alcoholic fatty liver disease in obese children and adolescents: a large cross-sectional study	19
Modified and alternative Baveno VI criteria based on age for ruling out high-risk varices in patients with compensated cirrhosis	18
Diet-derived antioxidants and nonalcoholic fatty liver disease: a Mendelian randomization study	18
Comments on: CT-based intratumoral and peritumoral radiomics to predict the treatment response to hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 in high-risk hepatocellular carcinoma	18
Impact of metabolic factors on risk of cardiovascular disease in nondiabetic metabolic dysfunction-associated fatty liver disease	18
Interferon therapy improves survival in patients with hepatitis B virus-related hepatocellular carcinoma after curative surgery: a meta-analysis	18
Explainable attention-enhanced heuristic paradigm for multi-view prognostic risk score development in hepatocellular carcinoma	18
Stem cells therapies for liver diseases: for current practice and future goals	18
Correction to: Linking the gut and liver: crosstalk between regulatory T cells and mucosa-associated invariant T cells	17
Lifestyle intervention for metabolic dysfunction-associated fatty liver disease: a 24-h integrated behavior perspective	17
Genetic predisposition of metabolic dysfunction-associated steatotic liver disease: a population-based genome-wide association study	17
CBX1 is involved in hepatocellular carcinoma progression and resistance to sorafenib and lenvatinib via IGF-1R/AKT/SNAIL signaling pathway	17
New progress towards elimination of mother-to-child transmission of hepatitis B virus in China	17
Oxidative stress triggers hyperdynamic circulation via central neural activation in portal hypertensive rats	17
Comment on “Cirrhotic cardiomyopathy in children with biliary atresia and genetic intrahepatic cholestasis: clinical course and outcomes”	17
The effectiveness of combination therapy with interferon and nucleoside analogs in pediatric patients with chronic hepatitis B: a systematic review and meta-analysis	17
Integrated genomic analyses of hepatocellular carcinoma	17
APASL STC on Alcohol Associated Liver Disease: Moscow 2025	17
Reduction of natural killer cells is associated with poor outcomes in patients with hepatitis B virus-related acute-on-chronic liver failure	17
Diagnosis and management of pediatric acute liver failure: consensus recommendations of the Indian Society of Pediatric Gastroenterology, Hepatology, and Nutrition (ISPGHAN)	16
Metabolic dysfunction-associated fatty liver disease and heavy alcohol consumption increase mortality:A nationwide study	16
Hepatitis B virus-related intrahepatic cholangiocarcinoma originates from hepatocytes	16
Reconsiderations for the liver donation from a living donor: addressing hepatic steatosis with weight loss preconditioning	16
Predictive models for functional cure in patients with CHB receiving PEG-IFN therapy based on HBsAg quantification through meta-analysis	16
The clinical implications and molecular features of intrahepatic cholangiocarcinoma with perineural invasion	16
Metabolic implications of tenofovir alafenamide in chronic hepatitis B: a commentary on cardiovascular and lipid risks	16
Commentary on “Predictive value of soluble PD-1 for HBsAg loss in HBeAg-negative chronic hepatitis B patients: a prospective study”	16
PIVKA-II combined with alpha-fetoprotein for the diagnostic value of hepatic tumors in children: a multicenter, prospective observational study	16
Messenger RNA electroporated hepatitis B virus (HBV) antigen-specific T cell receptor (TCR) redirected T cell therapy is well-tolerated in patients with recurrent HBV-related hepatocellular carcinoma	16
Diversity of the nucleic acid forms of circulating HBV in chronically infected patients and its impact on viral cycle	16
PIRO-CIC model can predict mortality and futility of care in critically ill cirrhosis patients in the intensive care unit	16
Editorial: The safety profile of endoscopic variceal ligation in patients with esophageal varices. Authors’ reply	15
Characteristics of microbiome-derived metabolomics according to the progression of alcoholic liver disease	15
Advancing personalized risk assessment in post-TIPS hepatic encephalopathy: insights and future directions	15
Effectiveness of entecavir vs tenofovir disoproxil fumarate for functional cure of chronic hepatitis B in an international cohort	15
Towards precise evaluation of steatotic liver disease subtypes and adverse pregnancy outcomes: methodological insights	15
Response to letters to editor "Next-Step Paradigms for Hepatitis B Functional Cure: Insights from the Anchor Combination Therapy Trial" and “Critical Appraisal of the Anchor RCT on Entecavir, Peginter	14
Clinical practice guidelines on hemochromatosis: Asian Pacific Association for the Study of the Liver	14
Expanding treatment indications in chronic hepatitis B: Should we treat all patients?	14
Nomograms should be noted	14
Reply to Letter to the Editor “Hepatic irAE, ICI continuation, and survival: need for robust evidence beyond initial observations”	14
Global burden of cirrhosis and liver cancer due to alcohol: the past, present, and the future	14
Gut-microbiome composition and function in progression of alcohol-associated liver disease: going beyond western experiences	14
Reply to: The best predictive model for post-SVR HCC: can it be universal?	14
Comment on “Efficacy and safety of atezolizumab and bevacizumab with or without TACE as first-line therapy for unresectable HCC: a multicenter cohort study”	14
Bridging expression profiles and clinical outcomes in HCC target selection	14
Refining meta-analyses in advanced biliary tract cancer	14
Acute variceal bleeding portends poor outcomes in patients with acute-on-chronic liver failure: a propensity score matched study from the APASL ACLF Research Consortium (AARC)	14
Predictive power of portal pressure gradient remeasured shortly after transjugular intrahepatic portosystemic shunt	14
Influence of shunt occlusion on liver volume and functions in hyperammonemic cirrhosis patients having large porto-systemic shunts: a randomized control trial	14
Comments on: Coronavirus disease (COVID-19) and the liver: a comprehensive systematic review and meta-analysis	14

Global, regional, and national burdens of cirrhosis in children and adolescents aged under 19 years from 1990 to 2019	14
Machine learning prediction of rapid HBsAg seroclearance at week 24 in inactive carriers treated with pegylated interferon	14
Hepatic irAE, ICI continuation, and survival: need for robust evidence beyond initial observations	14
Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment	14
Correction to: Infuence of shunt occlusion on liver volume and functions in hyperammonemic cirrhosis patients having large porto-systemic shunts: a randomized control trial	13
How non-alcoholic fatty liver disease and cirrhosis affect the heart	13
The upregulation of Annexin A2 by TLR4 pathway facilitates lipid accumulation and liver injury via blocking AMPK/mTOR-mediated autophagy flux during the development of non-alcoholic fatty liver diseas	13
Comment on “Cirrhotic cardiomyopathy in children with biliary atresia and genetic intrahepatic cholestasis: clinical course and outcomes”	13
Developing real-world prognostic models for patients with advanced hepatocellular carcinoma: CRAFITY, mALF and beyond	13
Methylated SEPT9 assay-based liquid biopsy as a biomarker in molecular targeted agent-treated hepatocellular carcinoma	13
Epidemiological characteristics in Shanghai and a prognostic nomogram for 90 day adverse outcomes in acute hepatitis E	13
Comparison of the prognostic models for mortality in idiosyncratic drug-induced liver injury	13
Current understanding and future perspectives on the impact of changing NAFLD to MAFLD on global epidemiology and clinical outcomes	13
Insights in a prospective investigation of cardiomyopathy in children with biliary atresia and hereditary intrahepatic cholestasis: focus on diagnosis, survival analysis, and bias control	13
Characteristics and long-term mortality of patients with non-MAFLD hepatic steatosis	13
Effects of antiviral therapy and drug withdrawal on postpartum hepatitis in pregnant women with chronic HBV infection	13
FXR overexpression promotes liver regeneration through inducing FGF2 activation in APAP-induced acute liver injury	13
Correction to: Complementary role of peripheral and central autonomic nervous system on insulin-like growth factor-1 activation to prevent fatty liver disease	13
Exosomal miR-200b-3p induce macrophage polarization by regulating transcriptional repressor ZEB1 in hepatocellular carcinoma	13
Response to Letter to Editor: “Systemic inflammation and prognosis in HCC: a closer look”	13
Liver fibrosis is associated with impaired bone mineralization and microstructure in obese individuals with non-alcoholic fatty liver disease	12
Methodological and safety considerations for combination immunotherapy and NA cessation in CHB	12
Synthetic miR-26a mimics delivered by tumor exosomes repress hepatocellular carcinoma through downregulating lymphoid enhancer factor 1	12
Midodrine plus propranolol: potential problems and controversies behind remarkable efficacy	12
Multi-omics analysis of the lactylation-driven microenvironment and non-invasive clinical translation in hepatocellular carcinoma	12
Regarding the role of post-transplant inflammatory cytokine signature on predicting tumor recurrence after liver transplantation for hepatocellular carcinoma	12
Re-examining the incremental benefit of TACE–TKI–PD-1 triplet therapy: time-related bias and treatment pathways in a real-world HCC cohort	12
Safety of right liver donation after improving steatosis through weight loss in living donors: a retrospective study	12
Presence of sarcopenia identifies a special group of lean NAFLD in middle-aged and older people	12
Comment on “Small extracellular vesicles derived from lipotoxic hepatocytes transport FASN to promote hepatic stellate cell activation”	12
Comparison of relaxed verses standard cut-offs of rotational thromboelastometry for guiding blood product use before invasive procedures in advanced cirrhosis: a randomized controlled trial	12
Comments on: Addition of midodrine to albumin reduces the incidence of complications of large-volume paracentesis: an RCT comparing midodrine, terlipressin, and albumins	12
APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024	12
BRIX1 activated by mTORC1-SP1 signaling regulates ribosome biogenesis and alternative splicing to promote hepatocellular carcinoma progression	12
Autophagy and extracellular vesicles in the liver endothelium: friends or foes?	12
Response to letter—Machine learning prediction of rapid HBsAg seroclearance at week 24 in inactive carriers treated with pegylated interferon	12
Whole-exome sequencing reveals the metastatic potential of hepatocellular carcinoma from the perspective of tumor and circulating tumor DNA	12
The incidence of spontaneous HBsAg loss in patients with different baseline HBsAg levels: a systematic review and meta-analysis	12
Key considerations in portal vein thrombosis management	12
AI in fatty liver diseases: insights from recent research trends	11
The causes of death in patients with nonalcoholic steatohepatitis following liver transplantation stratified using pre-liver transplant BMI	11
Risk stratification for patients with primary biliary cholangitis: early versus advanced-stage or non-cirrhosis versus cirrhosis?	11
Von Willebrand factor processing in patients with advanced chronic liver disease and its relation to portal hypertension and clinical outcome	11
Management of spontaneous portosystemic shunts at the time of liver transplantation: treatment or observation? Results of a systematic review	11
Acute kidney injury stage 1a increases mortality of patients with cirrhosis: a prospective multicenter cohort study	11
Letter to the Editor: “Critical appraisal of MASLD subtypes and pregnancy outcome associations in a nationwide cohort”	11
Complications of congenital portosystemic shunts: liver tumors are affected by shunt severity, but pulmonary and neurocognitive associations are not	11
The combination of ropeginterferon alfa-2b with anti-PD1 blockage in adjuvant therapy in HBV-related HCC	11
Comment on “Metabolic dysfunction-associated steatotic liver disease and adverse pregnancy outcomes: a nationwide cohort study”	11
Identification of PANoptosis-relevant subgroups and predicting signature to evaluate the prognosis and immune landscape of patients with biliary tract cancer	11
Impact of plasma exchange on bilirubin reduction and neurological impairment in infantile acute liver failure	11
Obesity and non-alcoholic steatohepatitis in immunotherapy for hepatocellular carcinoma	10
Impact of myosteatosis on outcomes after liver transplantation: a systematic review and meta-analysis	10
Functional cure is associated with younger age in children undergoing antiviral treatment for active chronic hepatitis B	10
HBV, antivirals, and immunoglobulins after liver transplantation: all that glitters is not gold	10
Metabolic interventions improve HBV envelope-specific T-cell responses in patients with chronic hepatitis B	10
Functional B cell deficiency promotes intrahepatic HBV replication and impairs the development of anti-HBV T cell responses	10
Real world tirzepatide treatment for fatty liver disease	10
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma	10
Management of acute variceal bleeding: updated APASL guidelines	10
Development and experimental verification of a prognosis model for cuproptosis-related subtypes in HCC	10
Revisiting diabetes and mortality in ALD-ACLF: methodological and clinical considerations	10
Response to: “Refining Surgical Indications for Hepatocellular Carcinoma in Patients with Clinically Significant Portal Hypertension”	10
Efficacy and safety of precision-guided transjugular extrahepatic portosystemic shunt (TEPS) in the management of cavernous transformation of the portal vein with portal hypertension: a case series	10
Inhibition of the U12-type splicing factor ZCRB1 mediates retention of the USP21 minor intron to suppress malignant progression in hepatocellular carcinoma	10
Quantifying depression in MASLD: A methodological reflection	10
Is laparoscopic hepatectomy superior to laparotomic hepatectomy? The debate continues	10
Enhancing the evaluation and management of MAFLD: a call for comprehensive assessments and social work integration	10
Unresolved heterogeneity in hepatic irAEs: critical limitations in prognostic interpretation for ICI-treated patients	10
Incidence, risk factors, and outcomes of acute liver injury in hospitalized adults with acute kidney injury: a large multicenter study	9
MAFLD as part of systemic metabolic dysregulation	9
Epidemiology, pathophysiology and clinical aspects of Hepatocellular Carcinoma in MAFLD patients	9
Inflammation of the liver, HCC development and HCC establishment	9
Consensus on the tertiary prevention of primary liver cancer	9
Albumin, filamin-A and cytokeratin 19 help distinguish intrahepatic cholangiocarcinoma from extrahepatic adenocarcinoma	9
Letter: Effects of dapagliflozin on liver steatosis in patients with nonalcoholic fatty liver disease: a randomized controlled trial	9
Effect of diabetes on mortality and liver transplantation in alcoholic liver cirrhotic patients with acute decompensation	9
Correction to: Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines	9
Alcohol-related hepatitis admissions decline in 2021 after a 2020 surge attributed to the COVID-19 pandemic	9
Commentary on "Comparative effectiveness of tirzepatide versus bariatric metabolic surgery in adults with metabolic-associated steatotic liver disease and obesity: a multi-institutional propensity sco	9
Long-term clinical outcomes of adults with metabolic dysfunction-associated fatty liver disease: a single-centre prospective cohort study with baseline liver biopsy	9
Comment on “Autoimmune liver diseases in the Asia Pacific region: proceedings of the autoimmune liver disease course at APASL 2025”	9
Epidemiology and outcomes of primary sclerosing cholangitis: an Australian multicentre retrospective cohort study	9
Midodrine with albumin synergy in refractory ascites management	9
Complementary role of peripheral and central autonomic nervous system on insulin-like growth factor-1 activation to prevent fatty liver disease	9
Comparison of diagnostic criteria for fatty liver disease in assessing cardiac dysfunction: a cross-sectional study	9
The clinical implications of pre-liver transplant diabetes on post-liver transplant outcomes in patients with NASH: analysis of the UNOS database	9
Burden, trends, and predictions of liver cancer in China, Japan, and South Korea: analysis based on the Global Burden of Disease Study 2021	9
Integrating single-cell and bulk RNA sequencing reveals CK19 + cancer stem cells and their specific SPP1 + tumor-associated macrophage niche in HBV-related hepatocellular carcinoma	9
Adipokine/hepatokines profiling of fatty liver in adolescents and young adults: cross-sectional and prospective analyses of the BCAMS study	9
Outcomes of pediatric living donor liver transplantation using steatotic grafts: expanding the donor pool for rising MASLD prevalence	9
Commentary on “Machine learning prediction of rapid HBsAg seroclearance at week 24 in inactive carriers treated with pegylated interferon	9
Lymphatic drainage dysfunction via narrowing of the lumen of cisterna chyli and thoracic duct after luminal dilation	9
Single-cell transcriptomic profiling reveals dysregulation of B-cell subset function in patients with chronic hepatitis B	9
Correction: Immunosuppression in adult liver transplant recipients: a 2024 update from the Italian Liver Transplant Working Group	9